Glenmark Pharmaceuticals Inc., USA, (BSE:532296) (NSE:GLENMARK), a subsidiary of India-based Glenmark Pharmaceuticals, and Cediprof, Inc, a part of the Mexico-based Neolpharma Pharmaceutical Group family of companies, announced on Thursday that they have entered into an exclusive supply and distribution agreement for Cediprof's FDA-approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5mg, 10mg, 15mg, 20mg and 30mg, the generic version of Adderall Tablets, 5mg, 10mg, 15mg, 20mg, and 30mg, of Teva Women's Health, Inc.
Glenmark expects to commence distribution of the product in the US during the second half of 2023. This product has long been on FDA's shortage list.
Brendan O'Grady, chief executive officer – Glenmark Global Formulations Business said, 'Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5mg, 10mg, 15mg, 20mg and 30mg is a highly prescribed medication in the United States. Glenmark is very pleased to be able to alleviate the shortage this country is facing by partnering with Cediprof and Neol.'
Accord Healthcare launches Lurasidone HCL tablets
US FDA Accepts the ATI-1501 NDA, According to Appili Therapeutics
Sanofi reports Q4 sales of Dupixent up 42%
Upsher-Smith Laboratories launches Fluoxetine Oral Solution, USP, 20mg/5mL
Astellas Pharma enters into Asset Purchase Agreement with Sandoz
ANI Pharmaceuticals Launches Levocarnitine Tablets USP Following US FDA Approval
Hartness Named to Bryn Pharma Board of Directors
Accord Healthcare adds Bendamustine Lyo. Injection to range of chemotherapy drugs
ANI Pharmaceuticals Receives FDA Approval, Launches Fluoxetine Oral Solution USP
ANI Pharmaceuticals receives FDA approval for Fluoxetine Oral Solution USP
Prasco Laboratories introduces Authorised Generic of ZIOPTAN in partnership with Thea Pharma
ANI Pharmaceuticals declares FDA approval and commercialisation of Trimethoprim Tablets USP
McKinley, Boothe Named to Maxwell Biosciences Board of Directors